6T-CEM Cells

Categories: Leukemia cell lines Description: The 6T-CEM cell line is a mutant derivative of the human acute lymphoblastic leukemia (ALL) T-cell line CCRF-CEM. It was developed by exposing the parent CEM cells to 6-thioguanine, leading to the selection of a subline that exhibits resistance to this compound. This resistance is a result of the inactivation of the HPRT gene, which is critical in the purine salvage pathway. The 6T-CEM cells have been particularly valuable in studying drug resistance mechanisms, especially concerning purine analogs like 6-thioguanine. Additionally, these cells are characterized by their secretion of a unique T-cell suppressor inducer factor (SIF), which is not only non-mitogenic and non-cytotoxic but also capable of suppressing T-cell proliferation while sparing B-cell proliferation at certain dilutions. 6T-CEM cells and their subclones, like 6T-CEM-20, have shown a significant increase in the production of this suppressor-inducer factor, which has potential applications in immunological research, particularly in the study of T-cell regulation and immune suppression. The SIF secreted by these cells has been shown to suppress up to 90% of mitogen-induced T-cell proliferation at extremely high dilutions (up to 10^-9), making these cells a potent model for exploring therapeutic strategies that involve modulation of the immune response. The use of these cells in various experimental setups has provided insights into the molecular underpinnings of immune suppression, with potential implications for the development of treatments for autoimmune diseases and in the context of organ transplantation to prevent graft rejection. Organism: Human Tissue: Peripheral blood Disease: T-cell acute lymphoblastic leukemia Synonyms: 6-T CEM Age: 4 years Gender: Female Ethnicity: Asian Morphology: Lymphoblast Growth Properties: Suspension Citation: 6T-CEM (Cytion catalog number 305132) Biosafety Level: 2 Ncbi_ Taxid: 9606.0 Cellosaurus Accession: CVCL_6869 Culture Medium: Alpha MEM, w: 2.0 mM stable Glutamine, w/o: Ribonucleosides, w/o: Deoxyribonucleosides, w: 1.0 mM Sodium pyruvate, w: 2.2g/L NaHCO3 Supplements: Supplement the medium with 10% FBS Subculturing: Gently homogenize the cell suspension in the flask by pipetting up and down, then take a representative sample to determine the cell density per ml. Dilute the suspension to achieve a cell concentration of 1 x 105 cells/ml with fresh culture medium, and aliquot the adjusted suspension into new flasks for further cultivation. Fluid Renewal: 2 to 3 times per week Freeze Medium: As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Thawing And Culturing Cells: Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks, for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes. Sterility: Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. Safety Precautions: When planning to store a cryovial in liquid nitrogen for future thawing, it is mandatory to adhere to stringent safety measures. Appropriate protective gloves and clothing are essential, and the use of a face mask or safety goggles is required during the transfer of frozen samples to or from the liquid nitrogen tank. This is to mitigate the risk of injury from potential cryovial explosions upon removal, which can result in the projection of sharp fragments. Warranty: We stand by the promise of delivering products with high cell viability and robust culture performance. To achieve the best results, please make sure you follow the storage and culture instructions detailed in the product information sheet closely. Your adherence to these guidelines is key to success. Subject To Material Transfer Agreements: If you intend to use Cytion cell lines solely for internal research at a single research site, please complete and sign our Material Transfer Agreement (MTA) and submit it along with your order.For any commercial applications - including but not limited to fee-for-service work, quality control testing, product release, diagnostic use, or regulatory studies - please complete the Intended Use Form so we can prepare a suitable agreement tailored to your project.Please note: The MTA applies only to certain cell lines. If this notice and the MTA document appear on a product page, the agreement is applicable. For cell lines not covered by the MTA, no reference to the agreement will be shown. The MTA is not valid for customers in the Americas, China, or Taiwan. Please contact our U.S. entity to receive the appropriate agreement. Required Product 3: 860015.0 Required Product 4: 830100.0